Warning: fopen(/home/virtual/epih/journal/upload/ip_log/ip_log_2025-02.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96
1Research Center for Health Sciences and Department of Epidemiology & Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.
2Department of Epidemiology & Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran.
© 2011, Korean Society of Epidemiology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Item | Recommendation | Not applicable | Not reported | Reported |
---|---|---|---|---|
1a | Indicate the study’s design in the title/abstract | 0 (0.0) | 15 (25.0) | 45 (75.0) |
1b | Provide in the abstract an informative and balanced summary | 0 (0.0) | 3 (5.0) | 57 (95.0) |
Introduction | ||||
2 | Explain the scientific background and rationale for the investigation | 0 (0.0) | 0 (0.0) | 60 (100.0) |
3 | State specific objectives, including any pre-specified hypotheses | 0 (0.0) | 1 (1.7) | 59 (98.3) |
Methods | ||||
4 | Present key elements of study design early in the paper | 0 (0.0) | 21 (35.0) | 39 (65.0) |
5 | Describe locations | 0 (0.0) | 2 (3.3) | 58 (96.7) |
5 | Describe recruitment dates | 0 (0.0) | 2 (3.3) | 58 (96.7) |
5 | Describe periods of follow-up | 0 (0.0) | 4 (6.7) | 56 (93.3) |
6a | Give the eligibility criteria | 0 (0.0) | 4 (6.7) | 56 (93.3) |
6a | Describe the methods of follow-up | 0 (0.0) | 2 (3.3) | 58 (96.7) |
6b | Give matching criteria | 54 (90.0) | 0 (0.0) | 6 (10.0) |
6b | Give number of exposed and unexposed in matched studies | 52 (86.7) | 5 (8.3) | 3 (5.0) |
7 | Clearly define all outcomes | 0 (0.0) | 0 (0.0) | 60 (100.0) |
7 | Clearly define all exposures | 0 (0.0) | 6 (10.0) | 54 (90.0) |
7 | Clearly define all predictors | 0 (0.0) | 2 (3.3) | 58 (96.7) |
7 | Clearly define all potential confounders | 0 (0.0) | 9 (15.0) | 51 (85.0) |
7 | Clearly define all effect modifiers | 0 (0.0) | 41 (68.3) | 19 (31.7) |
8 | Give sources of data | 0 (0.0) | 0 (0.0) | 60 (100.0) |
8 | Method of measurement | 0 (0.0) | 1 (1.7) | 59 (98.3) |
9 | Describe any efforts to address potential sources of bias | 0 (0.0) | 51 (85.0) | 9 (15.0) |
10 | Explain how the study size was arrived at | 33 (55.0) | 15 (25.0) | 12 (20.0) |
11 | Describe which groupings were chosen (if applicable) | 10 (16.7) | 8 (13.3) | 42 (70.0) |
12a | Describe all statistical methods | 0 (0.0) | 0 (0.0) | 60 (100.0) |
12a | Describe all statistical software | 0 (0.0) | 14 (23.3) | 46 (76.7) |
12b | Describe any methods used to examine subgroups and interaction | 0 (0.0) | 42 (70.0) | 18 (30.0) |
12c | Explain how missing data were addressed | 0 (0.0) | 33 (55.0) | 27 (45.0) |
12d | explain how loss to follow-up was addressed | 3 (5.0) | 42 (70.0) | 15 (25.0) |
12e | Describe any sensitivity analyses | 3 (5.0) | 44 (73.3) | 0 (21.7) |
Results | ||||
13a | Report numbers of individuals at each stage of study | 5 (8.3) | 29 (48.4) | 26 (43.3) |
13b | Give reasons for non-participation at each stage | 5 (8.3) | 42 (70.0) | 13 (21.7) |
13c | Consider use of a flow diagram | 0 (0.0) | 51 (85.0) | 9 (15.0) |
14a | Give characteristics of study participants | 0 (0.0) | 5 (8.3) | 55 (81.7) |
14b | Indicate the number of participants with missing data | 4 (6.7) | 37 (61.6) | 19 (31.7) |
14c | Summarize follow-up time | 2 (3.3) | 32 (53.4) | 26 (43.3) |
15 | Report numbers of outcome events or summary measures | 0 (0.0) | 0 (0.0) | 60 (100.0) |
16a | Give unadjusted estimates | 0 (0.0) | 23 (38.3) | 37 (61.7) |
16a | Give confounder-adjusted estimates | 1 (1.7) | 6 (10.0) | 53 (88.3) |
16a | Give estimates precision/confidence interval | 0 (0.0) | 2 (3.3) | 58 (96.7) |
16b | Report category boundaries when continuous variables were categorized | 8 (13.3) | 7 (11.7) | 45 (75.0) |
16c | Consider translating estimates of relative risk into absolute risk (If relevant) | 21 (35.0) | 32 (53.3) | 7 (11.7) |
17 | Report other analyses done e.g., subgroups analysis and sensitivity analyses | 0 (0.0) | 19 (31.7) | 41 (68.3) |
Discussion | ||||
18 | Summarize key results with reference to study objectives | 0 (0.0) | 0 (0.0) | 60 (100.0) |
19 | Discuss limitations of the study | 0 (0.0) | 0 (0.0) | 60 (100.0) |
20 | Give a cautious interpretation of results considering objectives | 0 (0.0) | 0 (0.0) | 60 (100.0) |
20 | Explain results from similar studies | 0 (0.0) | 0 (0.0) | 60 (100.0) |
21 | Discuss the generalizability of the study results | 0 (0.0) | 6 (10.0) | 54 (90.0) |
Other information | ||||
22 | Give the source of funding and the role of the funders | 0 (0.0) | 1 (1.7) | 59 (98.3) |
1-22 | Total | (7.1) | (23.6) | (69.3) |
STOBE, The Strengthening the Reporting of Observational Studies in Epidemiology.